Bhavarth S Shukla1,2, Samuel Shelburne2,3, Katherine Reyes4, Mini Kamboj5, Jessica D Lewis6, Sandra L Rincon1,7, Jinnethe Reyes7, Lina P Carvajal7, Diana Panesso1,7, Costi D Sifri6, Marcus J Zervos4,8, Eric G Pamer5, Truc T Tran1, Javier Adachi2, Jose M Munita1,9, Rodrigo Hasbun1, Cesar A Arias1,7. 1. University of Texas Medical School at Houston. 2. Department of Infectious Diseases. 3. Genomic Medicine, M.D. Anderson Cancer Center, Houston, Texas. 4. Department of Internal Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan. 5. Memorial Sloan Kettering Cancer Center, New York, New York. 6. Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville. 7. Molecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia. 8. Wayne State University School of Medicine, Detroit, Michigan. 9. Clinica Alemana, Universidad del Desarrollo, Santiago, Chile.
Abstract
BACKGROUND: Daptomycin has become a front-line antibiotic for multidrug-resistant Enterococcus faecium bloodstream infections (BSIs). We previously showed that E. faecium strains with daptomycin minimum inhibitory concentrations (MICs) in the higher end of susceptibility frequently harbor mutations associated with daptomycin resistance. We postulate that patients with E. faecium BSIs exhibiting daptomycin MICs of 3-4 µg/mL treated with daptomycin are more likely to have worse clinical outcomes than those exhibiting daptomycin MICs ≤2 µg/mL. METHODS: We conducted a multicenter retrospective cohort study that included adult patients with E. faecium BSI for whom initial isolates, follow-up blood culture data, and daptomycin administration data were available. A central laboratory performed standardized daptomycin MIC testing for all isolates. The primary outcome was microbiologic failure, defined as clearance of bacteremia ≥4 days after the index blood culture. The secondary outcome was all-cause in-hospital mortality. RESULTS: A total of 62 patients were included. Thirty-one patients were infected with isolates that exhibited daptomycin MICs of 3-4 µg/mL. Overall, 34 patients had microbiologic failure and 25 died during hospitalization. In a multivariate logistic regression model, daptomycin MICs of 3-4 µg/mL (odds ratio [OR], 4.7 [1.37-16.12]; P = .014) and immunosuppression (OR, 5.32 [1.20-23.54]; P = .028) were significantly associated with microbiologic failure. Initial daptomycin dose of ≥8 mg/kg was not significantly associated with evaluated outcomes. CONCLUSIONS: Daptomycin MICs of 3-4 µg/mL in the initial E. faecium blood isolate predicted microbiological failure of daptomycin therapy, suggesting that modification in the daptomycin breakpoint for enterococci should be considered.
BACKGROUND:Daptomycin has become a front-line antibiotic for multidrug-resistant Enterococcus faecium bloodstream infections (BSIs). We previously showed that E. faecium strains with daptomycin minimum inhibitory concentrations (MICs) in the higher end of susceptibility frequently harbor mutations associated with daptomycin resistance. We postulate that patients with E. faecium BSIs exhibiting daptomycin MICs of 3-4 µg/mL treated with daptomycin are more likely to have worse clinical outcomes than those exhibiting daptomycin MICs ≤2 µg/mL. METHODS: We conducted a multicenter retrospective cohort study that included adult patients with E. faecium BSI for whom initial isolates, follow-up blood culture data, and daptomycin administration data were available. A central laboratory performed standardized daptomycin MIC testing for all isolates. The primary outcome was microbiologic failure, defined as clearance of bacteremia ≥4 days after the index blood culture. The secondary outcome was all-cause in-hospital mortality. RESULTS: A total of 62 patients were included. Thirty-one patients were infected with isolates that exhibited daptomycin MICs of 3-4 µg/mL. Overall, 34 patients had microbiologic failure and 25 died during hospitalization. In a multivariate logistic regression model, daptomycin MICs of 3-4 µg/mL (odds ratio [OR], 4.7 [1.37-16.12]; P = .014) and immunosuppression (OR, 5.32 [1.20-23.54]; P = .028) were significantly associated with microbiologic failure. Initial daptomycin dose of ≥8 mg/kg was not significantly associated with evaluated outcomes. CONCLUSIONS:Daptomycin MICs of 3-4 µg/mL in the initial E. faecium blood isolate predicted microbiological failure of daptomycin therapy, suggesting that modification in the daptomycin breakpoint for enterococci should be considered.
Authors: James S Lewis; Aaron Owens; Jose Cadena; Kathryn Sabol; Jan E Patterson; James H Jorgensen Journal: Antimicrob Agents Chemother Date: 2005-04 Impact factor: 5.191
Authors: F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan Journal: J Clin Microbiol Date: 1995-09 Impact factor: 5.948
Authors: Alicia I Hidron; Jonathan R Edwards; Jean Patel; Teresa C Horan; Dawn M Sievert; Daniel A Pollock; Scott K Fridkin Journal: Infect Control Hosp Epidemiol Date: 2008-11 Impact factor: 3.254
Authors: Clare L Kinnear; Twisha S Patel; Carol L Young; Vincent Marshall; Duane W Newton; Andrew F Read; Robert J Woods Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191
Authors: Shelley A Campeau; Audrey N Schuetz; Peggy Kohner; Cesar A Arias; Peera Hemarajata; Jennifer Dien Bard; Romney M Humphries Journal: Antimicrob Agents Chemother Date: 2018-08-27 Impact factor: 5.191
Authors: Farnaz Foolad; Brandie D Taylor; Samuel A Shelburne; Cesar A Arias; Samuel L Aitken Journal: J Antimicrob Chemother Date: 2018-09-01 Impact factor: 5.790
Authors: Cecilia G Carvalhaes; Helio S Sader; Robert K Flamm; Jennifer M Streit; Rodrigo E Mendes Journal: Antimicrob Agents Chemother Date: 2020-03-24 Impact factor: 5.191